Natera, Inc.
NTRANasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 10/30234% above fair value
$378.92−35.38 (-8.54%)
Close on Nov 2, 2026Market cap $54.62BP/E –Yield –
Natera Cost of Licensing and Other Revenues by Quarter
Cost of Licensing and Other Revenues ($M) ($M)
Natera Cost of Licensing and Other Revenues: $1M in Q2 2026, up 100.0% from a year earlier.
Latest, Q2 2026
1
Period ended Jun 30, 2026
Change on a year earlier
+100.0%
0.50 in Q2 2025
History
38 quarters
Since Q1 2017
Sources
29
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (2026-08-07) ↗
Reported in Form 10-K/10-Q (DB).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Cost of Licensing and Other Revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 1 | +100.0% | Form 10-Q (2026-08-07) ↗ |
| Q1 2026 | Mar 31, 2026 | 0.60 | +20.0% | Form 10-Q (2026-05-08) ↗ |
| Q4 2025 | Dec 31, 2025 | 0.80 | +60.0% | Form 10-K (2026-02-27) ↗ |
| Q3 2025 | Sep 30, 2025 | 0.50 | +25.0% | Form 10-Q (2025-11-07) ↗ |
| Q2 2025 | Jun 30, 2025 | 0.50 | +66.7% | Form 10-Q (2025-08-08) ↗ |
| Q1 2025 | Mar 31, 2025 | 0.50 | +66.7% | Form 10-Q (2025-05-09) ↗ |
| Q4 2024 | Dec 31, 2024 | 0.50 | +150.0% | Form 10-K (2025-02-28) ↗ |
| Q3 2024 | Sep 30, 2024 | 0.40 | +33.3% | Form 10-Q (2024-11-12) ↗ |
| Q2 2024 | Jun 30, 2024 | 0.30 | 0.0% | Form 10-Q (2024-08-09) ↗ |
| Q1 2024 | Mar 31, 2024 | 0.30 | -25.0% | Form 10-Q (2024-05-10) ↗ |
| Q4 2023 | Dec 31, 2023 | 0.20 | -60.0% | Form 10-K (2024-02-29) ↗ |
| Q3 2023 | Sep 30, 2023 | 0.30 | -72.7% | Form 10-Q (2023-11-09) ↗ |
| Q2 2023 | Jun 30, 2023 | 0.30 | -40.0% | Form 10-Q (2023-08-04) ↗ |
| Q1 2023 | Mar 31, 2023 | 0.40 | -20.0% | Form 10-Q (2023-05-10) ↗ |
| Q4 2022 | Dec 31, 2022 | 0.50 | -37.5% | Form 10-K (2023-03-01) ↗ |
| Q3 2022 | Sep 30, 2022 | 1.10 | +22.2% | Form 10-Q (2022-11-09) ↗ |
| Q2 2022 | Jun 30, 2022 | 0.50 | -16.7% | Form 10-Q (2022-08-05) ↗ |
| Q1 2022 | Mar 31, 2022 | 0.50 | -50.0% | Form 10-Q (2022-05-06) ↗ |
| Q4 2021 | Dec 31, 2021 | 0.80 | -84.3% | Form 10-K (2023-03-01) ↗ |
| Q3 2021 | Sep 30, 2021 | 0.90 | -81.6% | Form 10-Q (2022-11-09) ↗ |
| Q2 2021 | Jun 30, 2021 | 0.60 | -85.7% | Form 10-Q (2022-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | 1 | -71.4% | Form 10-Q (2022-05-06) ↗ |
| Q4 2020 | Dec 31, 2020 | 5.10 | +2.0% | Form 10-K (2021-02-26) ↗ |
| Q3 2020 | Sep 30, 2020 | 4.90 | +32.4% | Form 10-Q (2020-11-06) ↗ |
| Q2 2020 | Jun 30, 2020 | 4.20 | +75.0% | Form 10-Q (2020-08-07) ↗ |
| Q1 2020 | Mar 31, 2020 | 3.50 | +105.9% | Form 10-Q (2020-05-08) ↗ |
| Q4 2019 | Dec 31, 2019 | 5 | +108.3% | Form 10-K (2020-03-02) ↗ |
| Q3 2019 | Sep 30, 2019 | 3.70 | +68.2% | Form 10-Q (2019-11-08) ↗ |
| Q2 2019 | Jun 30, 2019 | 2.40 | +33.3% | Form 10-Q (2019-08-09) ↗ |
| Q1 2019 | Mar 31, 2019 | 1.70 | +13.3% | Form 10-Q (2019-05-10) ↗ |
| Q4 2018 | Dec 31, 2018 | 2.40 | +50.0% | Form 10-K (2020-03-02) ↗ |
| Q3 2018 | Sep 30, 2018 | 2.20 | +100.0% | Form 10-Q (2018-11-09) ↗ |
| Q2 2018 | Jun 30, 2018 | 1.80 | +125.0% | Form 10-Q (2018-08-09) ↗ |
| Q1 2018 | Mar 31, 2018 | 1.50 | +150.0% | Form 10-Q (2018-03-31) ↗ |
| Q4 2017 | Dec 31, 2017 | 1.60 | – | Form 10-K (2020-03-02) ↗ |
| Q3 2017 | Sep 30, 2017 | 1.10 | – | Form 10-Q (2018-11-09) ↗ |
| Q2 2017 | Jun 30, 2017 | 0.80 | – | Form 10-Q (2018-08-09) ↗ |
| Q1 2017 | Mar 31, 2017 | 0.60 | – | Form 10-Q (2018-03-31) ↗ |
Cite this data
StockData. (2026). Natera Cost of Licensing and Other Revenues ($M), quarterly Q1 2017–Q2 2026 [Data set]. Compiled from Natera SEC filings and investor materials. https://stockdatahq.com/stocks/ntra/kpis/db-seg-licensing-cor
See every metric in the Natera KPI table. Data updated Nov 2, 2026.